A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer
NCT00037518 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46
Last updated 2013-05-08
Summary
This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.
Conditions
- Hyperparathyroidism
- Parathyroid Neoplasms
Interventions
- DRUG
-
AMG 073
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-04-30
More Related Trials
-
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
NCT00089674 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
NCT07259213 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
NCT05352178 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674 ·Status: RECRUITING ·Phase: PHASE3
-
Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer
NCT00077402 ·Status: COMPLETED ·Phase: PHASE2
-
Study of HPN424 in Patients With Advanced Prostate Cancer
NCT03577028 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
NCT00770848 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946 ·Status: RECRUITING ·Phase: PHASE3
-
Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer
NCT01817738 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Proton Therapy for High Risk Prostate Cancer
NCT01811810 ·Status: WITHDRAWN ·Phase: NA
-
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
NCT01228760 ·Status: COMPLETED ·Phase: PHASE1
-
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
NCT00118092 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01283373 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02705469 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
NCT04253483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
NCT03570827 ·Status: COMPLETED ·Phase: PHASE2
-
Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer
NCT00969202 ·Status: UNKNOWN ·Phase: PHASE1
-
3-AP in Treating Patients With Advanced Prostate Cancer
NCT00054015 ·Status: COMPLETED ·Phase: PHASE2
-
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
NCT03039439 ·Status: RECRUITING
-
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
NCT05100472 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02711956 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00471718 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT04704505 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
NCT02518698 ·Status: COMPLETED